Acoustoelectric Echocardiography for Improving Prognosis & Guiding Treatment Decisions for Advanced Arrhythmias

声电超声心动图改善预后

基本信息

批准号：
10082323
负责人：
RAYMOND Bruce RUNYAN
金额：
$ 26.3万
依托单位：
ELECTROSONIX, LLC
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-21 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10082323
关键词：
Ablation Affect Animal Model Arizona Arrhythmia Atrial Fibrillation Automobile Driving Brain Businesses Cardiac Cessation of life Chest wall structure Chronic Clinic Clinical Complex Detection Development Diagnosis Diagnostic Diagnostic Imaging Disease Progression EKG P Wave EKG QRS Complex Echocardiography Electrocardiogram Electrodes Equipment Family suidae Farming environment Frequencies Functional disorder Goals Heart Heart Atrium Heart failure Hospitalization Image Imaging technology Impairment Implant Industry Lead Legal patent Licensing Maps Medical Device Medical Errors Methods Miniature Swine Modeling Outcome Patient-Focused Outcomes Patients Performance Pharmacology Population Quality of life Real-Time Systems Resolution Signal Transduction Skin Speed Surface System Techniques Technology Tissues Translating Ultrasonography Universities Vision accurate diagnosis base diagnostic accuracy embolic stroke experience heart function heart imaging heart rhythm imaging modality imaging system improved in vivo in vivo evaluation instrumentation monitoring device mortality non-invasive imaging noninvasive diagnosis novel outcome forecast point of care portability radio frequency signal processing success validation studies

项目摘要

ABSTRACT Atrial Fibrillation (AF) is characterized by a disorganized activation of the atrium leading to impaired cardiac function and more serious complications like embolic stroke, worsening heart failure, and increased mortality. AE affects 9% of the U.S. population (2% younger than 65) and contributes to 750,000 hospitalizations and 130,000 deaths per year. There is a clear unmet clinical need for a novel noninvasive imaging modality able to accurately diagnose, classify, and localize the origin of advanced arrythmias like AF with the goal of making better treatment decisions and improving patient outcomes. The objectives of this proposal are to develop, optimize, and validate the first transthoracic Acoustoelectric Cardiac Imaging (tACI) system for real-time, high resolution mapping of cardiac currents and arrythmias through the chest wall. This patented technology combines ultrasound with high frequency radiofrequency recording to remotely map electrical currents in the body (e.g., heart, brain) at high resolution. If successful, tACI will achieve noninvasive electrical mapping of the ventricles and atria at the mm and ms scales, thereby providing high diagnostic accuracy for classifying advanced arrythmias like AF, localizing its origins, guiding treatment decisions and reducing medical errors, leading to better outcomes for patients. The long-term goal at ElectroSonix is to commercialize and translate revolutionary and portable ACI technology to the clinic, doctor’s office, and point-of-care for improving diagnosis and treatment for all types of arrythmias. The global cardiac diagnostic and monitoring devices market is expected to surpass $10 billion by 2020, growing at 4.0% CAGR, while the specific market for noninvasive diagnostic imaging (e.g., ECG) is expected to reach $1 billion globally by 2025 at a CAGR of 2.0%. A clinical system based on tACI technology would impact this sector by greatly improving the accuracy for diagnosing and classifying arrythmias. Further, by localizing the origins of arrythmias, the proposed clinical tACI system would help guide treatment decisions, reduce medical errors, and improve quality of life for patients suffering from AF and other advanced arrythmias.

抽象的心房颤动 (AF) 的特点是心房激活紊乱，导致心脏功能受损功能和更严重的并发症，如栓塞性中风、心力衰竭恶化和死亡率增加。 AE 影响 9% 的美国人口（2% 65 岁以下），导致 750,000 人住院治疗，每年有 130,000 人死亡，对于一种能够准确诊断、分类和定位 AF 等晚期心律失常的起源，目标是该提案的目标是制定更好的治疗决策和改善患者的治疗结果。优化并验证第一个经胸声电心脏成像 (tACI) 系统，可实现实时、高这项专利技术结合了通过胸壁的心脏电流和心律失常的分辨率映射。具有高频射频记录的超声波可远程绘制体内电流图（例如，如果成功，tACI 将实现心室的无创电测绘。和心房的 mm 和 ms 等级，从而为晚期心律失常的分类提供高诊断准确性像 AF 一样，定位其起源，指导治疗决策并减少医疗错误，从而获得更好的结果 ElectroSonix 的长期目标是商业化和转化革命性的便携式 ACI。将技术引入诊所、医生办公室和护理点，以改善所有类型的诊断和治疗全球心脏诊断和监测设备市场预计将超过 100 亿美元。 2020 年，复合年增长率为 4.0%，而无创诊断成像（例如心电图）的特定市场是预计到 2025 年，全球销售额将达到 10 亿美元，复合年增长率为 2.0% 基于 tACI 技术的临床系统。将通过极大地提高心律失常的诊断和分类的准确性来影响该领域。通过定位心律失常的起源，拟议的临床 tACI 系统将有助于指导治疗决策，减少医疗失误，提高房颤和其他晚期心律失常患者的生活质量。